Immunocore (NASDAQ:IMCR) Receives Buy Rating from HC Wainwright

Immunocore (NASDAQ:IMCR - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $100.00 target price on the stock. HC Wainwright's price objective indicates a potential upside of 207.69% from the company's previous close.

IMCR has been the topic of a number of other reports. Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Oppenheimer restated an "outperform" rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. JPMorgan Chase & Co. dropped their target price on shares of Immunocore from $70.00 to $66.00 and set an "overweight" rating for the company in a report on Wednesday, July 10th. Morgan Stanley reduced their target price on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Finally, UBS Group assumed coverage on shares of Immunocore in a research report on Thursday. They set a "sell" rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $75.17.

Immunocore Price Performance

Shares of IMCR stock traded up $0.48 during mid-day trading on Thursday, hitting $32.50. 274,069 shares of the stock were exchanged, compared to its average volume of 541,900. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The company has a market cap of $1.63 billion, a PE ratio of -25.90 and a beta of 0.72. The firm has a fifty day moving average of $33.48 and a 200 day moving average of $41.40.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.25. The company had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. Immunocore's quarterly revenue was up 26.2% compared to the same quarter last year. During the same period last year, the company earned ($0.37) earnings per share. Research analysts anticipate that Immunocore will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Immunocore by 71.4% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 21,232 shares of the company's stock valued at $1,380,000 after purchasing an additional 8,848 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Immunocore by 2.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company's stock worth $5,695,000 after buying an additional 1,830 shares during the period. Capstone Investment Advisors LLC acquired a new stake in shares of Immunocore during the first quarter valued at about $1,227,000. FORA Capital LLC purchased a new stake in shares of Immunocore in the 1st quarter valued at approximately $777,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Immunocore by 86.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company's stock worth $22,230,000 after acquiring an additional 158,455 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.